Capri Global Capital Limited
5,608words
2turns
0analyst exchanges
0executives
Key numbers — 40 extracted
Rs37,688
91%
7%
Rs133,621
54%
8%
50%
Rs28,884
84%
20%
Rs289
47%
Guidance — 6 items
Follow us
opening
“Total Locations (Branches + Feet-on-Street) i : Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 322 450 714 714 714 Note: Political map of India not to scale C A P R I G L O B A L 11 I Car Loan Origination: On Track To Cross Rs100bn In Originations In FY24 Consistently Rising Loan Originations (₹ Mn)^ l.”
Follow us
opening
“Well Capitalized For Medium Term Growth =···································································································································································1,.”
Follow us
opening
“The Company is well capitalised for medium term growth.”
Follow us
opening
“•· CAGR of 24% FY19-FY23 '····: ............”
Note
opening
“No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.”
Note
opening
“Any opinion, estimate or projection herein constitutes a judgment as of the date of this Presentation, and there can be no assurance that future results or events will be consistent with any such opinion, estimate or projection.”
Advertisement
Risks & concerns — 2 flagged
* ATS = Originations by Value / Originations by Volume During Quarter C A P R I G L O B A L 12 Earnings Performance C A P R I G L O B A L 13 Performance Matrix : Operating Profit Up Despite NII Decline .
— Follow us
-1 Spreads (YoA – CoF) (%) •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• O3FY24 O2FY24 7.0% 6.6% 6.6% A higher rise in CoF led to 9bps spread compression O4FY23 01 FY24 O2FY24 O3FY24 6.2% I O3FY23 O3FY23 O4FY23 01 FY24 O2FY24 O3FY24 Net Interest Margin (%) 9.6% 9.4% 8.6% 8.5% I I O4FY23 O3FY23 ··1 9.0% { / NIM decline reflects higher average borrowings in Q3 vs.
— Follow us
Speaking time
1
1
Advertisement
Opening remarks
Follow us
000 1 Business Performance C A P R I G L O B A L 2 I Key Highlights ❑ Housing and Gold Loan drive business momentum; disbursals touched Rs37,688mn (91% YoY, 7% QoQ) while Cons. AUM increased to Rs133,621mn (54% YoY, 8% QoQ). Gold Loan disbursals constituted 50% of consolidated disbursals during Q3FY24. ❑ Car loan originations touched Rs28,884mn (84% YoY, 20% QoQ), net fee contribution from the business at Rs289mn in Q3FY24. Wholly-owned subsidiary ‘Capri Loans Car Platform Pvt. Ltd.’ became functional and began accruing income during Q3FY24. ❑ Spread compression, albeit marginal, continued leading to sequential dip in NII. However, robust fees from car loan origination and lending businesses supported net income growth of 47% YoY and 6% QoQ. ❑ C/I ratio declined by a sharp 392bps QoQ to 63% as overall opex stayed flat QoQ aided by a pause in aggressive Gold Loan branch expansion. ❑ Proactive provisioning to raise PCR continued leading to a softer sequential PAT momentum. Cons. PAT was
Note
1. Average of market capitalization on BSE and NSE on 31st December ‘23. 2. 1 US$ = ₹ 83.17 3. Not adjusted for DTAs; ₹ 36.9bn after adjusting for DTAs; 4. 5. The Board of Directors have approved a split from Rs2/- face value to Re1/- face value at the Board Meeting held on 27th January’24. This is subject to shareholder approval. The Board of Directors have also approved a 1:1 bonus issue subject to shareholder approval. 6. AMFI classifies CGCL as a small cap company based on six monthly average market capitalization (Dec’23 rank 306). 7. CGCL is part of NIFTY Smallcap 250 index. C A P R I G L O B A L 37 Leadership C A P R I G L O B A L 38 I Board of Directors Independent Board Guides Executive Management Ajit Mohan Sharan, Independent Director IAS - Batch 1979 with over 3 decades of experience in varied aspects of public administration Beni Prasad Rauka, Independent Director Group CFO- Advanced Enzyme Technologies; over 2.5+ decades of experience; CA &CS Lingam Venkata Prabhakar, Add
Advertisement